NVAX rises impending an earnings report LONG

업데이트됨

Today NVAX is selling for a tiny fraction of its all-time high as shown in a previous idea. Earnings

is coming this upcoming week. This week NVAX news release showed it had settled a years long

litigation over a failed COVID. In the face of earnings around the corner, was this news release

a coincidence or instead a case of excellent executive and legal timing? I will skip the

conspiracy discussion.

On the chart, NVAX's bullish momentum is clear on its face. A price rise of 22% from a stock

that has been stuck in deeply undervalued territory for a significant time period is remarkable.

I have bought far out of the money call options into 2025 and 2026 some only this past month.

Those from this month are now up over 250% with 11 and 23 months to go to expiration.

I see NVAX as a risky penny medical stock with a high reward potential relative to the

risk. It is a potential buy-out candidate and bankruptcy is less likely. The rich uncle is

MRNA but the richer uncle in PFE might gain some interest. The wisest of capitalists buy out

the competition when there is an opportunity and do not worry about the government crying

monopoly when life-saving and life-extending medical products are involved. Time will tell.

I expect insane profits.

액티브 트레이드

Another idea if you like deeply undervalued biotech penny stocks with upcoming earnings

노트